StockWatch
·
Q2 FY-2027 RESULTS · COSMOFIRST

Cosmo First Q2 FY27: consolidated PAT ₹99 Cr, +58% adjusted YoY; OPM slips to 10.3%

PAT +111.22% YoY · revenue +51.02% · margins compressing

Q2 FY27 resultsCOSMOFIRSTCosmo First Ltd03 Nov 2026 · 3 min read
Revenue

₹1,387.86 Cr

+51.02% YoY

PAT (consolidated)

₹98.58 Cr

+111.22% YoY

Net margin

6.93%

+2pp YoY

EPS

₹37.98

Cosmo First's consolidated (primary) Q2 FY27 print shows revenue of ₹1,387.86 Cr, up 51.0% YoY (18.3% QoQ) from ₹919.03 Cr, and net profit of ₹98.58 Cr, up 111.2% YoY from ₹46.69 Cr. The reported PAT jump is materially flattered by two items: a ₹24.81 Cr one-off gain at the US subsidiary from a customs-duty refund on prior-year import tariffs (Note 5), and a swing to a net tax credit of ₹0.39 Cr (from ₹10.62 Cr tax a year ago) after the company adopted the concessional tax regime under the new Income Tax Act, 2025. Stripping just the customs refund, adjusted PAT is ~₹73.77 Cr, still up a strong 58.0% YoY and ahead of revenue growth — but the headline +111% is not a clean read of underlying profitability. Standalone PAT of ₹58.62 Cr against ₹98.58 Cr consolidated makes the same point: the gap is almost entirely the US one-off sitting at the subsidiary level.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹1,387.86 Cr+19.1%+51%
Expenses₹1,323.17 Cr+19.7%+49.2%
PAT₹98.58 Cr+83.4%+111.22%
Net margin6.93%+2.4pp+2pp
EPS₹37.98+83.4%+110.2%

Operating margin actually compressed this quarter: OPM (EBITDA/revenue) fell to ~10.3% from 11.2% a year ago and 11.6% last quarter, as cost of materials consumed rose to 69.5% of revenue from 67.1% YoY — raw-material cost pressure that also shows up at the segment level, where Packaging Films (71% of revenue, +49.3% YoY) saw its segment margin slip to 11.6% from 12.9% YoY even as segment profit grew 33.9%. The headline net-margin expansion (NPM ~7.1% vs 4.9% YoY) is therefore largely a tax-and-one-off artefact sitting on top of a core business whose unit economics got slightly worse.

₹
681.88760.2838.53916.85995.1776507-3108-2409-1610-0911-03Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹765, down 7.5% over the past month of trading.

₹ Cr
036.873.61110.4142.87Q1 FY26rev ₹800 Cr46.69Q2 FY26rev ₹919 Cr29.5Q3 FY26rev ₹899 Cr36.91Q4 FY26rev ₹1,021 Cr53.75Q1 FY27rev ₹1,166 Cr98.58Q2 FY27rev ₹1,388 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

Consolidated basic EPS ₹37.98 vs ₹18.07 a year ago (+110%) — diluted ₹37.41.

What management guided (1 FY-2027 call)
FY27 topline growth ~20% with commensurate PAT growth. New businesses (Specialty Chemicals, Plastech, Consumer, Zigly) expected to grow ~60%. US exports to grow 25-30% post-tariff rationalization. ROCE target 15-20% over next 12-24 months. Net debt/EBITDA to fall below 2x within 12 months, ₹400-500 Cr debt reduction pl

— This quarter: beat

Against management's FY27 guidance of ~20% topline growth with "commensurate" PAT growth, this quarter's 51% revenue growth and 58% adjusted PAT growth run well ahead of pace — a continuation of the Q1 FY27 beat (+46% revenue, +25% PAT). The four new businesses (Specialty Chemicals, Plastech, Consumer, Petcare) grew a combined 78.9% YoY to ₹156 Cr, ahead of the ~60% target management set for them; Specialty Chemicals segment profit grew 59.5% YoY, while Cosmo Consumer and Petcare losses widened to ₹5.35 Cr and ₹14.89 Cr respectively as Zigly expanded via the Prolife Speciality Vet Clinic acquisition that closed September 29, 2026. The company also incorporated a 50:50 flexible-packaging JV with Filmax Corporation (Korea) during the half. No consensus estimate for this specific quarter turned up via search, so vs-Street cannot be assessed; no separate management press release was available to cross-check framing.

  • W1

    OPM trajectory next quarter once the one-off US refund and the currently near-zero tax rate normalize — this quarter's OPM was 10.3% vs 11.2-11.6% in the prior two quarters.

  • W2

    New-businesses growth sustaining above the ~60% FY27 target (currently 78.9% YoY) as Petcare/Zigly scales post the Prolife acquisition, and whether Consumer/Petcare losses (₹5.35 Cr / ₹14.89 Cr this quarter) narrow.

  • W3

    Progress toward management's sub-2x net debt/EBITDA (within 12 months) and ₹400-500 Cr debt-reduction target — standalone borrowings stood at ₹1,400.67 Cr as of 30 Sep 2026.

Informational and educational content only. Not investment advice.